Akebia Therapeutics, Inc.
AKBA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $58,766 | $62,472 | $57,336 | $46,497 |
| % Growth | -5.9% | 9% | 23.3% | – |
| Cost of Goods Sold | $9,701 | $9,919 | $7,625 | $20,365 |
| Gross Profit | $49,065 | $52,553 | $49,711 | $26,132 |
| % Margin | 83.5% | 84.1% | 86.7% | 56.2% |
| R&D Expenses | $14,626 | $11,013 | $9,754 | $11,786 |
| G&A Expenses | $0 | $0 | $0 | $23,075 |
| SG&A Expenses | $29,990 | $26,555 | $25,742 | $27,675 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $4,600 |
| Other Operating Expenses | $0 | $896 | $701 | $978 |
| Operating Expenses | $44,616 | $38,464 | $36,197 | $40,439 |
| Operating Income | $4,449 | $14,089 | $13,514 | -$14,307 |
| % Margin | 7.6% | 22.6% | 23.6% | -30.8% |
| Other Income/Exp. Net | -$3,294 | -$13,842 | -$7,402 | -$8,497 |
| Pre-Tax Income | $1,155 | $247 | $6,112 | -$22,804 |
| Tax Expense | $615 | $0 | $0 | $0 |
| Net Income | $540 | $247 | $6,112 | -$22,804 |
| % Margin | 0.9% | 0.4% | 10.7% | -49% |
| EPS | 0.002 | 0.001 | 0.026 | -0.1 |
| % Growth | 122.2% | -96.5% | 126% | – |
| EPS Diluted | 0.002 | 0.001 | 0.025 | -0.1 |
| Weighted Avg Shares Out | 264,786 | 262,566 | 235,498 | 218,699 |
| Weighted Avg Shares Out Dil | 274,373 | 271,104 | 241,603 | 218,699 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4,748 | $6,834 | $7,770 | $6,877 |
| Depreciation & Amortization | $318 | $316 | $314 | $9,345 |
| EBITDA | $6,221 | $7,397 | $14,196 | -$6,582 |
| % Margin | 10.6% | 11.8% | 24.8% | -14.2% |